A Zer1, L Domachevsky2,3, Y Rapson4, M Nidam5, D Flex1, A M Allen1, S M Stemmer1, D Groshar5,6, H Bernstine5,6. 1. Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. 2. Department of Nuclear Medicine, Rabin Medical Center, Petah Tikva, Israel. liranura@gmail.com. 3. Beilinson Hospital, 39 Jabotinski St., Petah Tikva, 4941492, Israel. liranura@gmail.com. 4. Department of Radiology, Rabin Medical Center, Petah Tikva, Israel. 5. Department of Nuclear Medicine, Rabin Medical Center, Petah Tikva, Israel. 6. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
BACKGROUND: We evaluated 18F-FDG PET/CT in small cell lung cancer (SCLC) staging and assessed metabolic (SUVmax, MTV and TLG) and morphologic (CTvol) variables as predictors for overall survival (OS) and progression-free survival (PFS). METHODS: Patients with newly diagnosed, histopathology-confirmed SCLC, who underwent 18F-FDG PET/CT were evaluated. A Cox proportional hazard model was used to determine the association between the primary tumour SUVmax, MTV, TLG and CTvol with OS and PFS. Similar evaluations were performed when hilar/mediastinal lymphadenopathy was included [total SUVmax (TSUVmax), total MTV (TMTV) and total TLG (TTLG)]. RESULTS: 55 patients were included. 18F-FDG PET/CT changed staging in 6/55 (10.9%) patients who were upstaged to extensive disease. TTLG (>443.8) was a significant variable for OS with HR=2.1 (CI 1.14-3.871, p=0.017). Patients with TTLG>443.8 had a median OS of 13.4 months compared to 25.7 months in patients with TTLG<443.8 (p=0.018). TMTV (>72.4) was significant for PFS with HR=2.3 (CI 1.11-4.8, p=0.025). A median PFS of 12.1 and 26.2 months was found with TMTV greater and less than 72.4, respectively (p=0.005). CONCLUSIONS: 18F-FDG PET/CT improved staging of patients with SCLC, and TTLG and TMTV can be used as prognostic variables for OS and PFS, respectively. KEY POINTS: • Identifying variables that predict the prognosis of patients with SCLC is important. • 18F-FDG PET/CT influences staging of patients with SCLC. • Metabolic parameters could be used as predictors for PFS and OS.
BACKGROUND: We evaluated 18F-FDG PET/CT in small cell lung cancer (SCLC) staging and assessed metabolic (SUVmax, MTV and TLG) and morphologic (CTvol) variables as predictors for overall survival (OS) and progression-free survival (PFS). METHODS:Patients with newly diagnosed, histopathology-confirmed SCLC, who underwent 18F-FDG PET/CT were evaluated. A Cox proportional hazard model was used to determine the association between the primary tumour SUVmax, MTV, TLG and CTvol with OS and PFS. Similar evaluations were performed when hilar/mediastinal lymphadenopathy was included [total SUVmax (TSUVmax), total MTV (TMTV) and total TLG (TTLG)]. RESULTS: 55 patients were included. 18F-FDG PET/CT changed staging in 6/55 (10.9%) patients who were upstaged to extensive disease. TTLG (>443.8) was a significant variable for OS with HR=2.1 (CI 1.14-3.871, p=0.017). Patients with TTLG>443.8 had a median OS of 13.4 months compared to 25.7 months in patients with TTLG<443.8 (p=0.018). TMTV (>72.4) was significant for PFS with HR=2.3 (CI 1.11-4.8, p=0.025). A median PFS of 12.1 and 26.2 months was found with TMTV greater and less than 72.4, respectively (p=0.005). CONCLUSIONS: 18F-FDG PET/CT improved staging of patients with SCLC, and TTLG and TMTV can be used as prognostic variables for OS and PFS, respectively. KEY POINTS: • Identifying variables that predict the prognosis of patients with SCLC is important. • 18F-FDG PET/CT influences staging of patients with SCLC. • Metabolic parameters could be used as predictors for PFS and OS.
Entities:
Keywords:
18F-FDG PET/CT; Metabolic parameters; Overall survival; Progression-free survival; Small cell lung cancer
Authors: B M Fischer; J Mortensen; S W Langer; A Loft; A K Berthelsen; B I Petersen; G Daugaard; U Lassen; H H Hansen Journal: Ann Oncol Date: 2006-10-23 Impact factor: 32.976
Authors: I Brink; T Schumacher; M Mix; S Ruhland; E Stoelben; W Digel; M Henke; N Ghanem; E Moser; E U Nitzsche Journal: Eur J Nucl Med Mol Imaging Date: 2004-07-17 Impact factor: 9.236
Authors: Sudeep J Karve; Gregory L Price; Keith L Davis; Gerhardt M Pohl; Emily Nash Smyth; Lee Bowman Journal: BMC Health Serv Res Date: 2014-11-13 Impact factor: 2.655
Authors: Prakash Manoharan; Ahmed Salem; Hitesh Mistry; Michael Gornall; Susan Harden; Peter Julyan; Imogen Locke; Jonathan McAleese; Rhona McMenemin; Nazia Mohammed; Michael Snee; Sarah Woods; Thomas Westwood; Corinne Faivre-Finn Journal: J Thorac Oncol Date: 2019-04-16 Impact factor: 15.609
Authors: M Unterrainer; C Eze; H Ilhan; S Marschner; O Roengvoraphoj; N S Schmidt-Hegemann; F Walter; W G Kunz; P Munck Af Rosenschöld; R Jeraj; N L Albert; A L Grosu; M Niyazi; P Bartenstein; C Belka Journal: Radiat Oncol Date: 2020-04-21 Impact factor: 3.481
Authors: Pablo Borrelli; José Luis Loaiza Góngora; Reza Kaboteh; Johannes Ulén; Olof Enqvist; Elin Trägårdh; Lars Edenbrandt Journal: EJNMMI Phys Date: 2022-02-03